Improvement in hereditary hemorrhagic telangiectasia after treatment with the multi-kinase inhibitor Sunitinib

Ann Hematol. 2016 Dec;95(12):2077-2078. doi: 10.1007/s00277-016-2796-6. Epub 2016 Aug 15.

Authors

Freya Droege¹, Kruthika Thangavelu², Stephan Lang², Urban Geisthoff²

Affiliations

¹ Department of Otorhinolaryngology, Head and Neck Surgery, University Hospital Essen, University Duisburg-Essen, Hufelandstrasse 55, 45147, Essen, Germany. freya.droege@uk-essen.de.
² Department of Otorhinolaryngology, Head and Neck Surgery, University Hospital Essen, University Duisburg-Essen, Hufelandstrasse 55, 45147, Essen, Germany.

PMID: 27525726
DOI: 10.1007/s00277-016-2796-6

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Aged
Follow-Up Studies
Humans
Indoles / therapeutic use*
Male
Protein Kinase Inhibitors / therapeutic use*
Pyrroles / therapeutic use*
Sunitinib
Telangiectasia, Hereditary Hemorrhagic / diagnosis*
Telangiectasia, Hereditary Hemorrhagic / drug therapy*
Treatment Outcome

Substances

Indoles
Protein Kinase Inhibitors
Pyrroles
Sunitinib